GSK plc Releases 2017 Annual Report and Outlines New Priorities
GSK plc has published its 2017 annual report, detailing financial performance that includes significant growth in turnover and operating profit. The company also outlined its new long-term strategic priorities.
GSK plc, a global science-led healthcare company, has released its 2017 Annual Report, providing a comprehensive overview of its financial performance and strategic direction. The report highlights a year of growth and outlines the company's future objectives.
In 2017, GSK reported a group turnover of £30.2 billion, an increase of 8% on an actual exchange rate (AER) basis. Total operating profit reached £6.7 billion, marking a 51% increase AER. Sales from new products grew by 57% AER, and adjusted earnings per share stood at 111.8 pence. Net cash flow from operating activities was £6.9 billion.
The company's Chief Executive Officer discussed the year's performance and introduced new long-term priorities focused on scientific innovation and operational excellence. GSK's strategy aims to deliver differentiated, high-quality healthcare products across its three global businesses: Pharmaceuticals, Vaccines, and Consumer Healthcare.
The annual report emphasizes GSK's commitment to research and development, particularly in areas such as HIV treatments and prevention, and vaccine development. The company reiterates its purpose to help people do more, feel better, and live longer.